"Through biotechnology and advanced imaging, we are working to identify high-risk patients earlier and offer personalized therapies."
Our Objectives
Develop novel 68Ga-labelled PET tracers and multi-marker PET/MR imaging protocols for improved atherosclerosis diagnosis.
Objective #1: Transformative Effect on Diagnosis
Develop bispecific antibodies (bsAbs), a next-generation targeted immunotherapy designed to promote plaque regression in atherosclerotic vascular disease (ASVD).
Objective #2: Transformative Effect on Therapy
1. Define plaque vulnerability by characterizing harmful and protective monocyte/macrophage (Mo/MP) subsets.
2. Identify molecular targets of human antibodies (HuAbs) and evaluate their potential as soluble biomarkers for ASVD.
Objective #3: Transformative Impact on ASVD Knowledge
Latest news
ABCardionostics at the Dutch Atherosclerosis Society congress 2026 (Utrecht)
June was a particularly active month for the ABCardionostics consortium,...
Read More
ABCardionostics at the NSFA Congress 2026 (Biarritz)
The ABCardionostics project represented by the CRMSB team was present...
Read More
Dr Florence Ottones successfully defends her HDR at the University of Bordeaux
On March 25, 2026, Dr Florence Ottones, member of the...
Read More
Post-Doctoral Position in Bioinformatics – Join the ABCardionostics Project
The ABCardionostics consortium is recruiting a Post-Doctoral Researcher in Bioinformatics...
Read More